Results for
"[search-keyword]"
Sponsor content
56 result(s) found, displaying 1 to 10
- AusPAR: ApretudeAustralian Public Assessment Report (AusPAR)AusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.
- APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle (377442)ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle.
- APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial (377474)ARTGAustralian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial.
- APRETUDE (ViiV Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: cabotegravir sodium, cabotegravir.
- AusPAR: Tivicay and Tivicay PDAustralian Public Assessment Report (AusPAR)TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.
- AusPAR: Fostemsavir trometamolAustralian Public Assessment Report (AusPAR)Australian Public Assessment Report for Fostemsavir trometamol
- TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle (340591)ARTGAustralian Register of Therapeutic Goods (ARTG) information for TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle.
- TIVICAY and TIVICAY PD (ViiV Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: dolutegravir and dolutegravir (as sodium).
- TIVICAY and TIVICAY PD (ViiV Healthcare Pty Ltd)Prescription medicine registrationActive ingredients: dolutegravir and dolutegravir (as sodium).
- Notice for cabotegravir (as sodium) and cabotegravir (ViiV Healthcare Pty Ltd)Designation or determinationPriority review